Ivabradine, heart failure and chronic kidney disease
Incidence and prevalence of congestive heart failure are raising, especially in western countries. In Europe and in the United States it represents a disabling clinical disease for all injured people and it's accountable for the increase of hospitalization and sanitary costs.
European guidelines have underlined the importance of the optimization of pharmacological treatment to improve both patients' outcomes and quality of life.
SHIFT trial's results, based on the evaluation of ivabradine's efficacy if added to conventional congestive heart failure's therapy, seem to proceed in that direction.
RedfieldM.M., JacobsenS.J., BurnettJ.C.. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.JAMA.2003; 289: 194–202.
2.
JouvenX., EmpanaJ.P., SchwartzP.J., DesnosM., CourbonD., DucimetièreP.. Heart-rate profile during exercise as a predictor of sudden death.N Engl J Med.2005; 352: 1951–8.
3.
CooneyM.T., VartiainenE., LaatikainenT., JuoleviA., DudinaA., GrahamI.M.. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women.Am Heart J.2010; 159: 612–9.
4.
BenetosA., ThomasF., BeanK., AlbaladejoP., PalatiniP., GuizeL.. Resting heart rate in older people: a predictor of survival to age 85.J Am Geriatr Soc.2003; 51: 284–5.
5.
BöhmM., SwedbergK., KomajdaM.. The association between heart rate and outcomes in a randomised placebo-controlled trial.Lancet.2010; 376: 886–94.
6.
LevyR.L., WhiteP.D.. Transient tachycardia. Prognostic significance alone and in association with transient hypertension.Med Press Egypt.1946; 38(6): 207–12.
7.
GiannoglouG.D., ChatzizisisY.S., ZamboulisC., ParcharidisG.E., MikhailidisD.P., LouridasG.E.. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms.Int J Cardiol.2008; 126: 302–12.
8.
HeidlandU.E., StrauerB.E.. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption.Circulation.2001; 104: 1477–82.
9.
KannelW.B., KannelC., PaffenbargerR.S.Jr., CupplesL.A.. Heart rate and cardiovascular mortality: the Framingham Study.Am Heart J.1987; 113: 1489–94.
10.
FoxK., BorerJ.S., CammA.J.. Resting heart rate in cardiovascular disease.J Am Coll Cardiol.2007; 50: 823–30.
11.
DiazA., BourassaM.G., GuertinM.C., TardifJ.C.. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.Eur Heart J.2005; 26: 967–74.
12.
HoJ.E., BittnerV., DemiccoD.A., BreaznaA., DeedwaniaP.C., WatersD.D.. Usefulness of heart rate at rest as a predictor of mortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (Data from the Treating to New Targets [TNT] trial).Am J Cardiol.2010; 105: 905–11.
13.
FerrariR.. Pathophysiological role of heart rate: from ischaemia to left ventricular dysfunction.Eur Heart J.2008; 10(Suppl. F): F7–10.
14.
TardifJ.C., FordI., TenderaM., BourassaM.G., FoxK.; INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.Eur Heart J.2005 Dec;26(23): 2529–36.
15.
TardifJ.C., PonikowskiP., KahanT.. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial.Eur Heart J.2009; 30: 540–8.
16.
Di Francesco, CammJ.A.. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.Drugs.2004; 64: 1757–65.
17.
ThollonC., CambarratC., VianJ., ProstJ.F., PeglionJ.L., VilaineJ.P.. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49.Brith J Pharmacol.1994; 112: 37–42.
18.
ColinP., GhalehB., MonnetX.. Contributions of heart rate and contractility to myocardial oxygen balance during exercise.Am J Physiol Heart Circ Physiol.2003; 284: H676–82.
19.
VoorsA.A., van VeldhuisenD.J., RobertsonM.. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT.Eur J Heart Fail.2014; 16(4): 426–34.
20.
TavazziL., SwedbergK., KomajdaM.. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.Int J Cardiol.2013; 170: 182–8.]
21.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.Eur Heart J.2012; 33: 1787–847.
22.
TenderaM., TalajicM., RobertsonM.. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.Lancet.2008; 372: 807–16.
23.
FoxK., FordI., StegP.G., TenderaM., RobertsonM., FerrariR.. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.Lancet.2008; 372: 817–21.
SwedbergK., KomajdaM., BöhmM., BorerJ.S., FordI., TavazziL.. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.Lancet.2010; 376: 875–85.
26.
SwedbergK., KomajdaM., BöhmM.. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.J Am Coll Cardiol.2012; 59: 1938–45.
27.
SchillerN.B., ShahP.M., CrawfordM.. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.J Am Soc Echocardiogr.1989; 2: 358–67.
28.
EkmanI., ChassanyO., KomajdaM.. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.Eur Heart J.2011; 32: 2395–404.
29.
TardifJ.C., O'MearaE., KomajdaM.. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.Eur Heart J.2011; 32: 2507–15.
30.
VolterraniM., CiceG., CaminitiG.. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial).Int J Cardiol.2011; 151: 218–24.
31.
CiceG., Di BenedettoA., D'AndreaA.. Heart rate as independent prognostic factor for mortality in normotensive hemodialysed patients.J Nephrol.2008; 21(5): 704–12.
